| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Tumor Biology, The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
The complexity of epithelial sialomucins was investigated by immunoprecipitation and membrane immunofluorescence, using monoclonal antibodies (MAbs) against MAM-6 and other sialomucins. MAbs against MAM-6 immunoprecipitated from a variety of sources either one or two sialylated glycoproteins with apparent molecular weights of over 400,000 under reducing as well as nonreducing conditions. The electrophoretic mobility of each MAM-6 glycoprotein as isolated from serum, milk, and cell lines of different individuals showed considerable variation. The differences in molecular weight of the MAM-6 glycoproteins were also reflected at the level of MAM-6 precursors which are less heavily glycosylated. Therefore, large differences in apparent molecular weight (150,000 and over) are most likely due to a variable protein backbone. We used this molecular polymorphism to prove that 11 MAbs against different sialomucins, obtained from various investigators, precipitated sialomucins generated from common precursor molecules.
The pattern of reactivity of the MAbs with carcinoma cell lines was complex. All but the two MAbs, directed against putative carbohydrate epitopes, immunoprecipitated the precursor molecule from each cell line. However, some of them were unable to immunoprecipitate the mature form of MAM-6 from these cell lines. These results indicate that those epitopes are masked, probably due to cell line- or possibly cell type-dependent variations in glycosylation of the epithelial sialomucin. Even within a single cell line mature molecules with different epitopes were observed. The differential reactivity of the MAbs was confirmed by membrane immunofluorescence. These results show that MAM-6 belongs to a family of epithelial sialomucins with a polymorphic protein backbone and extensive variation in glycosylation.
1 Supported by the Netherlands Cancer Foundation (K. W. F.).
Received 8/11/88. Revised 11/ 3/88. Accepted 11/11/88.
This article has been cited by other articles:
![]() |
R L Ten Berge, F G M Snijdewint, S von Mensdorff-Pouilly, R J J Poort-Keesom, J J Oudejans, J W R Meijer, R Willemze, J Hilgers, and C J L M Meijer MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form J. Clin. Pathol., December 1, 2001; 54(12): 933 - 939. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lin, V. Tsuprun, H. Kawano, M. M. Paparella, Z. Zhang, R. Anway, and S. B. Ho Characterization of mucins in human middle ear and Eustachian tube Am J Physiol Lung Cell Mol Physiol, June 1, 2001; 280(6): L1157 - L1167. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. O. Lloyd, J. Burchell, V. Kudryashov, B. W.T. Yin, and J. Taylor-Papadimitriou Comparison of O-Linked Carbohydrate Chains in MUC-1 Mucin from Normal Breast Epithelial Cell Lines and Breast Carcinoma Cell Lines. DEMONSTRATION OF SIMPLER AND FEWER GLYCAN CHAINS IN TUMOR CELLS J. Biol. Chem., December 27, 1996; 271(52): 33325 - 33334. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. C. Gaemers, H. L. Vos, H. H. Volders, S. W. van der Valk, and J. Hilkens A STAT-responsive Element in the Promoter of the Episialin/MUC1 Gene Is Involved in Its Overexpression in Carcinoma Cells J. Biol. Chem., February 23, 2001; 276(9): 6191 - 6199. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |